![logo2](/ServeContent?url=http%3A%2F%2Fwww.heterocycles.jp%2Fclockss%2Fimg%2Fcycle.gif)
![logo2](/ServeContent?url=http%3A%2F%2Fwww.heterocycles.jp%2Fclockss%2Fimg%2Flogo_box.gif)
HETEROCYCLES
An International Journal for Reviews and Communications in Heterocyclic ChemistryWeb Edition ISSN: 1881-0942
Published online by The Japan Institute of Heterocyclic Chemistry
e-Journal
Full Text HTML
Received, 9th March, 2011, Accepted, 5th April, 2011, Published online, 7th April, 2011.
DOI: 10.3987/COM-11-12204
■ Purinium Derivatives with Antitumor Activities from Heterostemma alatum Wight
Wen-Wei Fu, Chang-Heng Tan,* Peng-Yu Zhuang, Shu-Min Yang, Hong-Feng Luo, Jun-Jie Tan, Ping Liu, and Da-Yuan Zhu
Department of Natural Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
Abstract
Heteromine I (1), a new purinium derivative, together with six known compounds, were isolated from the aerial parts of Heterostemma alatum Wight. The structure of 1 has been established as 2-methylamino-6-methoxy-7,9-dimethyl-8-purinone by means of spectroscopic analysis. Two puriniums, heteromines J (2) and K (3) were isolated as natural products for the first time. Heteromine D (4) showed strong cytotoxicity against HL-60 cell line with IC50 of 4.04 nmol/mL.Heterostemma alatum Wight (Asclepiadaceae) is a liana that is distributed over the south and the southwest of China, Nepal, and India. Its roots or whole plant were used as a Chinese folk medicine for expelling dampness and detoxifying.1 A few phytochemical studies on plants of the genus Heterostemma reported the isolation of steroids, fatty acids, flavonoids, flavonoid glycosides, adenines, uridines, puriniums and pyrimidines from H. brownii 2-4 and H. alatum.5 Further exploration of the title plant led to the isolation of a new purinium derivative, heteromine I (1), two first obtained natural puriniums, heteromines J (2) and K (3), and four know compounds. The structure of 1 is elucidated as 2-methylamino-6-methoxy-7,9-dimethyl-8-purinone on the basis of spectroscopic analysis. Those known compounds are identified to be 2-dimethylamino-6-methoxy-7,9-dimethyl-8-purinone (2),4 6-methoxy-9- methyl-2-dimethylaminopurinium (3),4,6,7 11-oxo-α-amyrin acetate,8 α-amyrin acetate,9 sitgmast-4-ene- 1,3-dione,10 and stigmast-4-en-3-one.11 An assay on cytotoxicity showed that heteromine D (4) had strong cytotoxicity against HL-60 cell line with IC50 of 4.04 nmol/mL in contrast with 6-mercaptopurine of 3.96 nmol/mL.
Heteromine I (1) was isolated as white amorphous powders. The molecular formula was determined to be C9H13N5O2 based on the pseudomolecular ion peak [M+Na]+ at m/z 246.0959 in the HR-ESI-MS. The IR spectrum exhibited absorptions at 3385 (N-H), 1703 (C=O), 1635 (C=C), 1608 (C=N), and 1294 (-NH-CH3) cm-1. The UV appeared the maximum absorptions at 205, 250 and 298 nm. The above evidences indicated a purinium derivative.3,4 The 1H-NMR spectrum of 1 showed signals for a methylamino group (δ 2.78, 3H, br s), two methyl groups attached on two quaternary amines (δ 3.18 and 3.31, each s), and a typical methoxy group (δ 3.92, s). The four methyls were easily assigned by the HMBC and ROESY cross-peaks (Figure 2), the structure of heteromine I (1) was assigned as 2-methyl-amino-6-methoxy-7,9-dimethyl-8- purinone.
Compounds 2 and 3, named heteromines J and K, were obtained from plant resource for the first time. As an analogue of 1, 2 was easily assigned its 1H and 13C signals in contrast with those of 1. The original assignments for C-2 (δ 153.6) and C-8 (δ 157.9) in the literature4 were reversed and revised. 2 and 3 had been reported as derivatives from heteromine A under treatment of NaBH4, following air oxidation.4 3 was also a key intermediate in the course of synthesis of heteromine A.6,7
All puriniums isolated from the title plant, including 1-3 and heteromines A, B, C, D (4), and F, were evaluated their cytotoxicities against tumor cell line HL-60 (human promyelocytic leukemia cell). The results showed that 4 had a comparable cytotoxic activity (IC50 = 4.04 nmol/mL) with that of 6-MP (6-mercaptopurine, IC50 = 3.96 nmol/mL).
EXPERIMENTAL
General Experimental Procedures: Optical rotations were measured using a Perkin-Elmer 341 polarimeter. IR spectra were recorded on a Nicolet Magna 750 FTIR (KBr) spectrometer. ESI-MS and HR-ESI-MS were obtained on an Esquire 3000plus and a Q-TOF-Ultima mass spectrometer, respectively. NMR spectra were recorded on a Bruker AM-400 NMR spectrometers, the chemical shift values are reported in ppm (δ) and coupling constants (J) are given in Hz. Silica gel (200-300, 400 mesh) and precoated plates of silica gel (HSGF-254) (Qingdao Haiyang Chemical Group Co., Qingdao) were used for column chromatography (CC) and TLC, respectively.
Plant Material: The aerial parts of H. alatum were collected in Xishuangbanna County, Yunnan Province, China, in July 2006. The plant were identified by Prof. J.-Y. Cui of Xishuangbanna Tropical Botanical Garden, CAS, China. A voucher specimen (No. 2006-64) was deposited in the Herbarium of Shanghai Institute of Materia Medica.
Extraction and Isolation: The dried aerial parts of H. alatum (5.0 kg) was extracted with 95% EtOH (25 L×3, each 3 d) at room temperature. The solvents were evaporated under reduced pressure to give 524 g residue. The concentrated extract was suspended in H2O (3 L) and partitioned successively with petroleum ether (PE), CHCl3, EtOAc to provide the PE- (80 g), CHCl3- (50 g), and EtOAc-soluble fraction (30 g). The EtOAc-soluble fraction (30 g) was subjected to CC of silica gel eluted with EtOAc-acetone (1:0 0:1) to afford Fr.E1−Fr.E8. Fr.E6 (2.1 g) was repeatedly chromatographed on silica gel columns with EtOAc-acetone (10:1‒5:1) to give 1 (11 mg), 2 (27 mg) and 3 (35 mg). By the similar procedures, 11-oxo-α-amyrin acetate (255 mg), α-amyrin acetate (50 mg), sitgmast-4-ene-1,3- dione (40 mg), and stigmast-4-en-3-one (9 mg) were obtained from the CHCl3-soluble fraction.
Assay of Cytotoxic Activity: HL-60 cells (ATCC, Rockville, MD) were grown in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum at 37 °C in humidified air with 5% CO2. Cytotoxicity in vitro was measured by the MTT method. Briefly, cells (1 × 104 per well) were seeded into 96-well plates and exposed to various concentrations of test compounds. After treatment for 72 h, 10 μL MTT at 5 mg/ml was added to each well. The cells were then incubated at 37 °C for another 4 h and then 10% sodium dodecyl sulfate (SDS) in 0.01 M HCl was added to each well. The absorbance was detected at 570 nm with a microplate reader (KLx808, Bio-Tek, USA). Cytotoxicity was expressed as a percentage of that of the control culture, and IC50 was given as the concentration (nmol/mL) required for 50% inhibition of cell growth.
Heteromine I (1): White amorphous powders. UV (MeOH) λmax: 205, 250, 298 nm; IR (KBr) νmax: 3385, 2945, 1703, 1635, 1608, 1562, 1504, 1398, 1294, 1196, 1132, 771, 582 cm-1; 1H-NMR (DMSO-d6, 400 MHz) δ: 3.92 (6-Me, 3H, s), 3.31 (7-Me, 3H, s), 3.18 (9-Me, 3H, s), 2.78 (2-Me, 3H, br s); 13C-NMR (DMSO-d6, 100 MHz) δ: 158.1 (C-2), 152.9 (C-6), 152.7 (C-8), 150.8 (C-4), 98.6 (C-5), 53.1 (6-Me), 29.0 (7-Me), 28.1 (2-NMe), 26.0 (9-Me); ESI-MS m/z 234 ([M+H]+), 246 ([M+Na]+), 469 ([2M+Na]+); HR-ESI-MS m/z: 246.0959 (calcd. for C9H13N5O2Na: 246.0967).
Heteromine J (2): White amorphous powders. UV (MeOH) λmax: 205, 250, 298 nm; IR (KBr) νmax: 2929, 1618, 1574, 1462, 1390, 1329, 1298, 1261, 1068, 787, 638 cm-1; 1H-NMR (DMSO-d6, 400 MHz) δ: 3.94 (6-Me, 3H, s), 3.43 (7-Me, 3H, s), 3.31 (9-Me, 3H, s), 3.11 (2-Me2, 6H, s); 13C-NMR (DMSO-d6, 100 MHz) δ: 157.8 (C-2), 153.5 (C-8), 153.3 (C-6), 150.9 (C-4), 98.7 (C-5), 52.9 (6-Me), 29.2 (7-Me), 37.1 (2-NMe2), 26.2 (9-Me); ESI-MS m/z: 238 ([M+H]+), 260 ([M+Na]+), 497 ([2M+Na]+).
ACKNOWLEDGEMENTS
This study was financial supported by grants from the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program” (Nos. 2009ZX09301-001 and 2009ZX09311-003), the National Science Foundation of China (No. 81072545), and China Postdoctoral Science Foundation (No. 20090460644).
References
1. The Editorial Committee of Chinese Materia Medica, Chinese Materia Medica, Shanghai: Shanghai Sci & Tech Publisher, 1999, 6, 364.
2. Y. L. Lin, H. P. Lee, J. C. Ou, and Y. H. Kuo, Chin. Pharm. J. (Taipei), 1994, 46, 115.
3. Y. L. Lin, H. P. Lee, J. C. Ou, and Y. H. Kuo, Heterocycles, 1996, 43, 781. CrossRef
4. Y. L. Lin, R. L. Huang, C. M. Chang, and Y. H. Kuo, J. Nat. Prod., 1997, 60, 982. CrossRef
5. P. Y. Zhuang, W. W. Fu, C. H. Tan, S. M. Yang, F. Liu, Z. X. Wang, and D. Y. Zhu, Nat. Prod. Res. Dev., 2009, 21, 963.
6. C. Peinador, J. M. Quintela, and M. J. Moreira, Tetrahedron, 1997, 53, 8269. CrossRef
7. H. Roggen, C. Charnock, and L.-L. Gundersen, Tetrahedron, 2009, 65, 5199. CrossRef
8. J.-P. Huang, Y.-M. Ma, J.-S. Jiang, and P.-C. Zhang, China J. Chin. Mat. Med., 2006, 31, 1166.
9. K. Shiojima, H. Suzuki, N. Kodera, H. Ageta, H.-C. Chang, and Y.-P. Chen, Chem. Pharm. Bull., 1996, 44, 509.
10. X. Fan, Y.-C. Du, and J.-X. Wei, China J. Chin. Mat. Med., 1994, 19, 734.
11. M. D. Greca, P. Monaco, and L. Previtera, J. Nat. Prod., 1990, 53, 1430 CrossRef